FIRST (Financial Resources and Treatment) Study
Prostate cancer is the most common cancer (excluding skin cancer) and a leading cause of cancer death among men in the United States, yet there is no consensus on the optimal treatment for prostate cancer. The various treatment options that are available can present a variety of economic consequences. As such, the financial impact on the household can vary by type of treatment selected and the need for follow-up therapies. Numerous clinical and sociodemographic factors can influence treatment selection. Clinical characteristics such as stage of disease at presentation, tumor grade, and symptoms have been shown to be significant predictors of treatment, and these factors can vary by race and socioeconomic status (SES), indicating a complex interaction among pre-treatment clinical characteristics and social factors.
The goal of this study is to develop a measure of financial well-being at a different point in the cancer continuum, post-diagnosis, and to investigate the association between dimensions of financial well-being and prostate cancer treatment selection and perceived quality of care.
Funding source: National Cancer Institute
NIH project title: Financial Well-Being Following Prostate Cancer Diagnosis (1 K01 CA16904101)